GC
MGNX icon

Globeflex Capital’s MacroGenics MGNX Stock Holding History

Globeflex Capital’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-36,700
Closed -$750K – 509
2016
Q4 		$750K Sell
36,700
-23
-0.1% -$579 0.19% 205
2016
Q3 		$1.1M Sell
36,723
-100
-0.3% -$2.97K 0.27% 128
2016
Q2 		$994K Hold
36,823
– – 0.27% 137
2016
Q1 		$690K Hold
36,823
– – 0.18% 188
2015
Q4 		$1.14M Sell
36,823
-28,500
-44% -$866K 0.3% 113
2015
Q3 		$1.4M Buy
65,323
+22,600
+53% +$709K 0.3% 89
2015
Q2 		$1.62M Sell
42,723
-100
-0.2% -$3.29K 0.3% 94
2015
Q1 		$1.34M Sell
42,823
-1,309
-3% -$44.4K 0.26% 140
2014
Q4 		$1.55M Sell
44,132
-5
-0% -$125 0.3% 105
2014
Q3 		$922K Sell
44,137
-79
-0.2% -$1.63K 0.1% 215
2014
Q2 		$960K Buy
+44,216
New +$930K 0.1% 231

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Globeflex Capital's MGNX Position: Q1 2017 in Review

Globeflex Capital sold out of MacroGenics (MGNX) in Q1 2017, closing a stake of 36,700 shares — an estimated $750K sold.

Globeflex Capital first reported a position in MGNX in Q2 2014 and held it in 11 quarters. The position peaked at $1.62M in Q2 2015. 111 funds tracked by Wall St. Rank hold MGNX as of Q1 2017.

  • Globeflex Capital reported no remaining MacroGenics position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 36,700 MacroGenics shares in Q1 2017, an estimated $750K.
  • Globeflex Capital first reported a position in MacroGenics in Q2 2014 and held it in 11 quarters.
  • Globeflex Capital's MacroGenics position peaked at $1.62M in Q2 2015.
  • 111 funds tracked by Wall St. Rank held MacroGenics as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.